ALKERMES, INC.
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
- Conditions
- Schizophrenia
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 338
- Registration Number
- NCT03919994
- Locations
- 🇺🇸
Alkermes Investigational Site, Salt Lake City, Utah, United States
Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT03668314
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT03610048
- Locations
- 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico
A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density
- Conditions
- HealthyAlzheimer Disease
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03577262
- Locations
- 🇳🇱
VU Medical Center, Dept. Radiology and Nuclear Medicine, Amsterdam, Netherlands
🇳🇱QPS Netherlands B.V., Groningen, Netherlands
🇳🇱University Medical Center Groningen, Nuclear Medicine and Molecular Imaging, Groningen, Netherlands
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Combination Product: Aripiprazole Lauroxil
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03345979
- Locations
- 🇺🇸
Alkermes Investigational Site, Richardson, Texas, United States
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
- Conditions
- Bipolar I DisorderSchizophreniaSchizophreniform Disorder
- Interventions
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 524
- Registration Number
- NCT03201757
- Locations
- 🇬🇧
Alkermes Investigational Site, Headington, United Kingdom
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
- Conditions
- Bipolar I DisorderSchizophreniform DisordersSchizophrenia
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 426
- Registration Number
- NCT03187769
- Locations
- 🇬🇧
Alkermes Investigational Site, Maidstone, United Kingdom
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: ALKS 5461 Placebo
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT03188185
- Locations
- 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico
🇺🇸Alkermes Investigative Site, Bellevue, Washington, United States
An Insulin Sensitivity Study in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02922426
- Locations
- 🇺🇸
Alkermes Investigational Site, Chula Vista, California, United States
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 266
- Registration Number
- NCT02873208
- Locations
- 🇵🇷
Alkermes Investigational Site, San Juan, Puerto Rico